Vaccinex LONG Vacinex is a tiny company, $74 million market cap and approximately 29 million shares outstanding. They have beat street earnings expectations the past 2 quarters and they are working with Merck and the "keytruda" drug for an Alzheimer's "proof of concept" study. If the drug performs like it should, well, than you can guess where the price goes. 15% held by insiders, 36% held by institutions - this is critical, and only a 2% short position because everybody knows where it's going. It has a $7 price target and with any decent volume it will get to that number in a hurry. Thoughts? Comments? NASDAQ:VCNX
